Vanessa A. Giunta

Associate
Vanessa A. Giunta

Vanessa A. Giunta

Associate

V-Card

LinkedIn

Vanessa Giunta joined Garfunkel Wild, P.C. in 2022. She works on regulatory, corporate, and transactional matters for clients including, but not limited to, hospitals, medical providers, ambulatory care facilities, physician practices, and other for-profit and not-for-profit entities. Vanessa also has experience working on clinical trial and grant award agreements with research sponsors.

Prior to joining the firm, Vanessa was a Public Health Law Program Legal Intern at the Centers for Disease Control and Prevention, a Research Fellow at the Gitenstein Institute for Health Law and Policy, and a Clinic Intern at the Robert W. Entenmann Veterans Law Clinic. Vanessa was also a Certified Pharmacy Technician at local pharmacy companies and a Director of Reimbursement for a long term care pharmacy.

While in law school, Vanessa had her Note published in the Hofstra Labor & Employment Law Journal and received the highest level of Hofstra Law’s Public Service Awards for completing over 750 hours of public service work.

August 13, 2024|Alerts

Preparing for the FTC’s Ban on Non-Competes

What is the Status of the Pending FTC Ban on Non-Compete Agreements? Many clients are asking whether the Federal Trade Commission (FTC) ban has gone into effect and, if not, what the status is currently.  As we reported previously, click HERE, the FTC enacted a nationwide ban on most non-compete agreements, subject to certain narrow exceptions, […]

July 24, 2024|Events

Protect Your Pharmacy’s Medicare and Medicaid Enrollment From Termination! 

Pharmacy revocations for non-compliance with Medicare Part B and Durable Medical Equipment, Prosthetics, Orthotics and Supplies enrollment requirements are on the rise. Garfunkel Wild’s latest webinar in our Compliance Webinar Series discusses common risks and provides strategies to protect your pharmacy.

June 24, 2024|Alerts

OIG Greenlights Gene Therapy Assistance Program

The U.S. Department of Health and Human Services, Office of Inspector General (OIG) posted a favorable Advisory Opinion (24-03) permitting a pharmaceutical manufacturer (Manufacturer) to provide financial assistance  to qualified patients undergoing its gene therapy treatment for two severe genetic conditions.

May 1, 2024|Events

Be Prepared! NYS OMIG’s 2024 Work Plan Provides an Audit Roadmap for Health Care Providers of All Types

Garfunkel’s Compliance Webinar Series rolls on with an examination of the 2024 Work Plan published by the New York State Office of Medicaid Inspector General (OMIG).  

April 25, 2024|Alerts

FTC Bans Non-Competes Across the Nation

On Tuesday, April 23, 2024, the Federal Trade Commission (FTC) promulgated a final rule banning most non-compete agreements, in any industry, and is set to become effective 120 days after its publication in the Federal Register (the “Final Rule”).

January 17, 2024|Alerts

OMIG’s 2024 Work Plan Gives Critical Insights into Program Integrity Initiatives

The New York State Office of the Medicaid Inspector General (OMIG) released its 2024 work plan in furtherance of its mission to coordinate and conduct activities to prevent, detect and investigate medical assistance program fraud, waste and abuse, and to recover improperly expended Medicaid funds.  

January 17, 2024|Alerts

OIG Issues Toolkit for Medicare Advantage Organizations

The U.S. Department of Health and Human Services, Office of Inspector General (OIG) released a new toolkit to help Medicare Advantage (MA) organizations replicate OIG audit methodologies to detect and correct inaccurate diagnosis codes in their own systems.  

January 17, 2024|Alerts

OIG Approves Creative Approach to Restructuring Medical Practice Partnerships

The U.S. Department of Health and Human Services, Office of Inspector General (OIG) posted a favorable Advisory Opinion (23-12) that allows a limited liability partnership (the Partnership) consisting of two classes of physician partners to make a one-time, voluntary redemption offer (offer) to individual partners when they reach age 67.  

March 24, 2023|Alerts

Provider Warning: Avoid Fake DEA Agents

Scammers have perpetuated a telephone fraud scheme attempting to extort money and personal identifiable information from healthcare providers by impersonating Drug Enforcement Administration (“DEA”) agents across the country.

Vanessa Giunta joined Garfunkel Wild, P.C. in 2022. She works on regulatory, corporate, and transactional matters for clients including, but not limited to, hospitals, medical providers, ambulatory care facilities, physician practices, and other for-profit and not-for-profit entities. Vanessa also has experience working on clinical trial and grant award agreements with research sponsors.

Prior to joining the firm, Vanessa was a Public Health Law Program Legal Intern at the Centers for Disease Control and Prevention, a Research Fellow at the Gitenstein Institute for Health Law and Policy, and a Clinic Intern at the Robert W. Entenmann Veterans Law Clinic. Vanessa was also a Certified Pharmacy Technician at local pharmacy companies and a Director of Reimbursement for a long term care pharmacy.

While in law school, Vanessa had her Note published in the Hofstra Labor & Employment Law Journal and received the highest level of Hofstra Law’s Public Service Awards for completing over 750 hours of public service work.

July 24, 2024

Protect Your Pharmacy’s Medicare and Medicaid Enrollment From Termination! 

Pharmacy revocations for non-compliance with Medicare Part B and Durable Medical Equipment, Prosthetics, Orthotics and Supplies enrollment requirements are on the rise. Garfunkel Wild’s latest webinar in our Compliance Webinar Series discusses common risks and provides strategies to protect your pharmacy.

June 24, 2024

OIG Greenlights Gene Therapy Assistance Program

The U.S. Department of Health and Human Services, Office of Inspector General (OIG) posted a favorable Advisory Opinion (24-03) permitting a pharmaceutical manufacturer (Manufacturer) to provide financial assistance  to qualified patients undergoing its gene therapy treatment for two severe genetic conditions.

May 1, 2024

Be Prepared! NYS OMIG’s 2024 Work Plan Provides an Audit Roadmap for Health Care Providers of All Types

Garfunkel’s Compliance Webinar Series rolls on with an examination of the 2024 Work Plan published by the New York State Office of Medicaid Inspector General (OMIG).  

April 25, 2024

FTC Bans Non-Competes Across the Nation

On Tuesday, April 23, 2024, the Federal Trade Commission (FTC) promulgated a final rule banning most non-compete agreements, in any industry, and is set to become effective 120 days after its publication in the Federal Register (the “Final Rule”).

January 17, 2024

OIG Approves Creative Approach to Restructuring Medical Practice Partnerships

The U.S. Department of Health and Human Services, Office of Inspector General (OIG) posted a favorable Advisory Opinion (23-12) that allows a limited liability partnership (the Partnership) consisting of two classes of physician partners to make a one-time, voluntary redemption offer (offer) to individual partners when they reach age 67.  

January 17, 2024

OIG Issues Toolkit for Medicare Advantage Organizations

The U.S. Department of Health and Human Services, Office of Inspector General (OIG) released a new toolkit to help Medicare Advantage (MA) organizations replicate OIG audit methodologies to detect and correct inaccurate diagnosis codes in their own systems.  

January 17, 2024

OMIG’s 2024 Work Plan Gives Critical Insights into Program Integrity Initiatives

The New York State Office of the Medicaid Inspector General (OMIG) released its 2024 work plan in furtherance of its mission to coordinate and conduct activities to prevent, detect and investigate medical assistance program fraud, waste and abuse, and to recover improperly expended Medicaid funds.  

March 24, 2023

Provider Warning: Avoid Fake DEA Agents

Scammers have perpetuated a telephone fraud scheme attempting to extort money and personal identifiable information from healthcare providers by impersonating Drug Enforcement Administration (“DEA”) agents across the country.

August 13, 2024

Preparing for the FTC’s Ban on Non-Competes

What is the Status of the Pending FTC Ban on Non-Compete Agreements? Many clients are asking whether the Federal Trade Commission (FTC) ban has gone into effect and, if not, what the status is currently.  As we reported previously, click HERE, the FTC enacted a nationwide ban on most non-compete agreements, subject to certain narrow exceptions, […]

August 13, 2024|Alerts

Preparing for the FTC’s Ban on Non-Competes

What is the Status of the Pending FTC Ban on Non-Compete Agreements? Many clients are asking whether the Federal Trade Commission (FTC) ban has gone into effect and, if not, what the status is currently.  As we reported previously, click HERE, the FTC enacted a nationwide ban on most non-compete agreements, subject to certain narrow exceptions, […]

July 24, 2024|Events

Protect Your Pharmacy’s Medicare and Medicaid Enrollment From Termination! 

Pharmacy revocations for non-compliance with Medicare Part B and Durable Medical Equipment, Prosthetics, Orthotics and Supplies enrollment requirements are on the rise. Garfunkel Wild’s latest webinar in our Compliance Webinar Series discusses common risks and provides strategies to protect your pharmacy.

June 24, 2024|Alerts

OIG Greenlights Gene Therapy Assistance Program

The U.S. Department of Health and Human Services, Office of Inspector General (OIG) posted a favorable Advisory Opinion (24-03) permitting a pharmaceutical manufacturer (Manufacturer) to provide financial assistance  to qualified patients undergoing its gene therapy treatment for two severe genetic conditions.

May 1, 2024|Events

Be Prepared! NYS OMIG’s 2024 Work Plan Provides an Audit Roadmap for Health Care Providers of All Types

Garfunkel’s Compliance Webinar Series rolls on with an examination of the 2024 Work Plan published by the New York State Office of Medicaid Inspector General (OMIG).  

April 25, 2024|Alerts

FTC Bans Non-Competes Across the Nation

On Tuesday, April 23, 2024, the Federal Trade Commission (FTC) promulgated a final rule banning most non-compete agreements, in any industry, and is set to become effective 120 days after its publication in the Federal Register (the “Final Rule”).

January 17, 2024|Alerts

OMIG’s 2024 Work Plan Gives Critical Insights into Program Integrity Initiatives

The New York State Office of the Medicaid Inspector General (OMIG) released its 2024 work plan in furtherance of its mission to coordinate and conduct activities to prevent, detect and investigate medical assistance program fraud, waste and abuse, and to recover improperly expended Medicaid funds.  

January 17, 2024|Alerts

OIG Issues Toolkit for Medicare Advantage Organizations

The U.S. Department of Health and Human Services, Office of Inspector General (OIG) released a new toolkit to help Medicare Advantage (MA) organizations replicate OIG audit methodologies to detect and correct inaccurate diagnosis codes in their own systems.  

January 17, 2024|Alerts

OIG Approves Creative Approach to Restructuring Medical Practice Partnerships

The U.S. Department of Health and Human Services, Office of Inspector General (OIG) posted a favorable Advisory Opinion (23-12) that allows a limited liability partnership (the Partnership) consisting of two classes of physician partners to make a one-time, voluntary redemption offer (offer) to individual partners when they reach age 67.  

March 24, 2023|Alerts

Provider Warning: Avoid Fake DEA Agents

Scammers have perpetuated a telephone fraud scheme attempting to extort money and personal identifiable information from healthcare providers by impersonating Drug Enforcement Administration (“DEA”) agents across the country.

Practices
Education
J.D.,
Hofstra University School of Law,


B.A.,
State University of New York (SUNY) Stonybrook,
Bar Admissions
  • New York
Court admissions